Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3667
M. Naqvi, G. D'ancona, A. West
Introduction: Medications prescribed for the management of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) are high risk and/or high cost. A specialist pharmacist was placed in an outpatient ILD clinic to manage all patients with ILD and IPF. Aims and objectives: This study aims to determine the impact of a specialist pharmacist in the management of ILD. We hypothesise that a pharmacist can have a significant positive impact on improving patient choice, patient understanding and adherence to therapy. Methods: On initiation of therapy, all patients were counselled on ILD, management options, monitoring and supply by the specialist pharmacist. All drug interactions were checked and deprescribing undertaken, where appropriate. Patients were reviewed on a regular basis to assess adherence to therapy, dose escalate, assess the incidence of adverse effects and manage where appropriate, undertake blood monitoring and supply of medications. Results: Over an 18 month period, an average of 125 patients were reviewed by the specialist pharmacist each month. There were a mean of 20 new referrals to initiate therapy per month. 116 interventions were undertaken by the specialist pharmacist, this included deprescribing of inappropriately prescribed medicines, managing interactions and adverse effects and ensuring appropriate doses were prescribed. Conclusions: This study demonstrates the vital role a specialist pharmacist plays in the ILD multidisciplinary team. The specialist pharmacist was able to undertake a number of significant interventions which may contribute to a low initial drop out rate and adherence to therapy.
{"title":"Impact of a specialist respiratory pharmacist in the management of interstitial lung disease","authors":"M. Naqvi, G. D'ancona, A. West","doi":"10.1183/13993003.CONGRESS-2018.PA3667","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3667","url":null,"abstract":"Introduction: Medications prescribed for the management of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) are high risk and/or high cost. A specialist pharmacist was placed in an outpatient ILD clinic to manage all patients with ILD and IPF. Aims and objectives: This study aims to determine the impact of a specialist pharmacist in the management of ILD. We hypothesise that a pharmacist can have a significant positive impact on improving patient choice, patient understanding and adherence to therapy. Methods: On initiation of therapy, all patients were counselled on ILD, management options, monitoring and supply by the specialist pharmacist. All drug interactions were checked and deprescribing undertaken, where appropriate. Patients were reviewed on a regular basis to assess adherence to therapy, dose escalate, assess the incidence of adverse effects and manage where appropriate, undertake blood monitoring and supply of medications. Results: Over an 18 month period, an average of 125 patients were reviewed by the specialist pharmacist each month. There were a mean of 20 new referrals to initiate therapy per month. 116 interventions were undertaken by the specialist pharmacist, this included deprescribing of inappropriately prescribed medicines, managing interactions and adverse effects and ensuring appropriate doses were prescribed. Conclusions: This study demonstrates the vital role a specialist pharmacist plays in the ILD multidisciplinary team. The specialist pharmacist was able to undertake a number of significant interventions which may contribute to a low initial drop out rate and adherence to therapy.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134582622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.OA3821
Sukhmani Sra, K. Myall, B. Lams, S. Agarwal, A. West
Introduction: Interstitial lung disease (ILD) commonly occurs in the context of Rheumatoid arthritis (RA), and is associated with significant morbidity and mortality. Rituximab is commonly used in the treatment of articular Rheumatoid arthritis and has been shown to be safe in patients with ILD. Aims and objectives: We aimed to study the effect of Rituximab treatment on the progression of RA-ILD as measured by decline in FVC and TLCO. Methods: A retrospective analysis of patients with RA treated at a tertiary referral centre in the United Kingdom between November 2016 and November 2018 was performed. Patients with at least 3 months’ follow up were included if they had at least two lung function tests performed. Decline was measured either from first administration of Rituximab or from first available lung function (no treatment group). Results: 44 patients were identified who met the study criteria. Patients had follow up of a median 23.5 (range 6-89) months. In the group treated with Rituximab, 9 of 26 patients (34.6%) progressed (defined by a decline in FVC of > 10% or TLCO of > 15% or death due to respiratory disease) at a median of 23 months (range 8-44). In the group that did not receive Rituximab, 11 of 18 patients (61.1%) had progression of disease at a median of 18 months (range 3-44). There was a trend towards significance (p=0.08) in rate of decline in FVC between the two groups favouring Rituximab. Conclusions: In patients with RA-ILD, Rituximab was associated with a slower rate of progression when measured by decline in lung function. This supports the use of Rituximab in the management RA-ILD and the development of robust trials.
{"title":"The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease","authors":"Sukhmani Sra, K. Myall, B. Lams, S. Agarwal, A. West","doi":"10.1183/13993003.CONGRESS-2018.OA3821","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA3821","url":null,"abstract":"Introduction: Interstitial lung disease (ILD) commonly occurs in the context of Rheumatoid arthritis (RA), and is associated with significant morbidity and mortality. Rituximab is commonly used in the treatment of articular Rheumatoid arthritis and has been shown to be safe in patients with ILD. Aims and objectives: We aimed to study the effect of Rituximab treatment on the progression of RA-ILD as measured by decline in FVC and TLCO. Methods: A retrospective analysis of patients with RA treated at a tertiary referral centre in the United Kingdom between November 2016 and November 2018 was performed. Patients with at least 3 months’ follow up were included if they had at least two lung function tests performed. Decline was measured either from first administration of Rituximab or from first available lung function (no treatment group). Results: 44 patients were identified who met the study criteria. Patients had follow up of a median 23.5 (range 6-89) months. In the group treated with Rituximab, 9 of 26 patients (34.6%) progressed (defined by a decline in FVC of > 10% or TLCO of > 15% or death due to respiratory disease) at a median of 23 months (range 8-44). In the group that did not receive Rituximab, 11 of 18 patients (61.1%) had progression of disease at a median of 18 months (range 3-44). There was a trend towards significance (p=0.08) in rate of decline in FVC between the two groups favouring Rituximab. Conclusions: In patients with RA-ILD, Rituximab was associated with a slower rate of progression when measured by decline in lung function. This supports the use of Rituximab in the management RA-ILD and the development of robust trials.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124817691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3653
N. A. Ingla, S. Cuerpo, F. Hernández-González, E. Barbeta, C. Lucena, M. Boada, G. Espinosa, R. Castellanos, O. Viñas, A. Xaubet, C. Agustí, S. Prieto, José Ramírez, M. Sánchez, J. Sellarés
{"title":"Late Breaking Abstract - SMOKING PREVALENCE AND CHARACTERIZATION OF PATIENTS AT DIAGNOSIS OF DIFFUSE INTERSTITIAL LUNG DISEASES","authors":"N. A. Ingla, S. Cuerpo, F. Hernández-González, E. Barbeta, C. Lucena, M. Boada, G. Espinosa, R. Castellanos, O. Viñas, A. Xaubet, C. Agustí, S. Prieto, José Ramírez, M. Sánchez, J. Sellarés","doi":"10.1183/13993003.CONGRESS-2018.PA3653","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3653","url":null,"abstract":"","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125547530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3658
A. Olson, T. Maher, M. Salisbury, V. Acciai, B. Mounir, M. Quaresma, Leila Zouad-Lejour, C. Wells, A. Fischer
Background: Idiopathic pulmonary fibrosis (IPF) is the classic fibrosing interstitial lung disease (ILD), but it accounts for Aims and objectives: To assess healthcare resource use and cost in non-IPF PF-ILD. Methods: We analysed US-based medical insurance claims over 3 years (2014–2016). Patients were considered to have ILD if they had ≥2 ILD claims and ≥1 pulmonologist visit during this period. To stabilise the dataset, patients were required to have ≥1 ILD claim per year and ≥2 medical claims in each half of each year. Here, patients with PF-ILD were defined as the subset of patients with non-IPF ILD with ≥4 pulmonologist visits in 2016 or ≥3 more pulmonologist visits in 2016 than in 2014. Results: Of 2517 patients with non-IPF ILD, 15% (n=373) were considered to have PF-ILD. Mean annual medical costs associated with ILD claims (2014–2016) were $35,364 in patients with PF-ILD compared to $20,211 in the overall ILD population. As expected, patients with PF-ILD had more ILD claims in 2016 at physician offices (7.6 vs 4.2) and hospitals (10.5 vs 4.7) compared to all ILD, suggestive of more severe disease with higher overall healthcare utilisation. Conclusion: Patients with PF-ILD have higher healthcare utilisation and costs compared to other ILD patients, highlighting the need for an improved understanding and management of PF-ILD.
背景:特发性肺纤维化(IPF)是典型的纤维化间质性肺疾病(ILD)，但其目的和目的是:评估非IPF肺纤维化间质性肺疾病的医疗资源使用和成本。方法:我们分析了3年来(2014-2016年)美国医疗保险索赔。如果患者在此期间有≥2次ILD索赔和≥1次肺科医生就诊，则认为患者患有ILD。为了稳定数据集，要求患者每年有≥1次ILD索赔，每年每半年有≥2次医疗索赔。这里，PF-ILD患者被定义为2016年就诊≥4次或2016年比2014年多就诊≥3次的非ipf ILD患者的子集。结果:在2517例非ipf患者中，15% (n=373)被认为患有PF-ILD。2014-2016年，PF-ILD患者与ILD索赔相关的平均年医疗费用为35,364美元，而整个ILD人群为20,211美元。正如预期的那样，与所有ILD相比，2016年PF-ILD患者在医生办公室(7.6 vs 4.2)和医院(10.5 vs 4.7)有更多的ILD索赔，这表明疾病更严重，整体医疗利用率更高。结论:与其他ILD患者相比，PF-ILD患者有更高的医疗保健利用率和成本，这突出了对PF-ILD的更好理解和管理的必要性。
{"title":"Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease","authors":"A. Olson, T. Maher, M. Salisbury, V. Acciai, B. Mounir, M. Quaresma, Leila Zouad-Lejour, C. Wells, A. Fischer","doi":"10.1183/13993003.CONGRESS-2018.PA3658","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3658","url":null,"abstract":"Background: Idiopathic pulmonary fibrosis (IPF) is the classic fibrosing interstitial lung disease (ILD), but it accounts for Aims and objectives: To assess healthcare resource use and cost in non-IPF PF-ILD. Methods: We analysed US-based medical insurance claims over 3 years (2014–2016). Patients were considered to have ILD if they had ≥2 ILD claims and ≥1 pulmonologist visit during this period. To stabilise the dataset, patients were required to have ≥1 ILD claim per year and ≥2 medical claims in each half of each year. Here, patients with PF-ILD were defined as the subset of patients with non-IPF ILD with ≥4 pulmonologist visits in 2016 or ≥3 more pulmonologist visits in 2016 than in 2014. Results: Of 2517 patients with non-IPF ILD, 15% (n=373) were considered to have PF-ILD. Mean annual medical costs associated with ILD claims (2014–2016) were $35,364 in patients with PF-ILD compared to $20,211 in the overall ILD population. As expected, patients with PF-ILD had more ILD claims in 2016 at physician offices (7.6 vs 4.2) and hospitals (10.5 vs 4.7) compared to all ILD, suggestive of more severe disease with higher overall healthcare utilisation. Conclusion: Patients with PF-ILD have higher healthcare utilisation and costs compared to other ILD patients, highlighting the need for an improved understanding and management of PF-ILD.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130500159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.OA3819
I. Roldán, Luis Santiago Ruiz, Gloria Pérez Rubio, M. Mejía, M. Montaño, R. F. Valencia
{"title":"Genetic variant in MMP2 increases the risk to develop autoantibodies in patients with Hypersensitivity Pneumonitis","authors":"I. Roldán, Luis Santiago Ruiz, Gloria Pérez Rubio, M. Mejía, M. Montaño, R. F. Valencia","doi":"10.1183/13993003.CONGRESS-2018.OA3819","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA3819","url":null,"abstract":"","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129867131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA3659
A. H. Rittig, O. Hilberg, A. Løkke
Introduction: Hypersensitivity pneumonitis (HP) is a rare interstitial lung disease (ILD), with an almost undescribed lethality. Very few studies have investigated HP on a national level. Aim: The aim of this study was to investigate incidence, survival rate and comorbidity of this disease nationwide in Denmark. Methods: Using the Danish National Patient Registry we identified all patients with a first-time diagnosis of HP between 1998 and 2010. Patients with HP were matched 1:4 with controls by gender, age, marital status and geography. Co-morbidity three years prior to diagnosis was explored by the Charlson index score. Survival rates were assessed using Kaplan-Meier curves and Hazard Ratios. Results: We identified 753 patients (men: 56.7%) during the observation period and an average HP-incidence of 63 pr. Year. More than half (388 patients = 51.5%) was below 50 years. Survival rates of HP were lower at all time points when compared to the matched control population. The highest mortality among patients with HP was observed during the first two years following initial diagnosis - revealing a higher mortality rate in the age groups 0-39 and 60-80+. Furthermore, patients had a significant higher Charlson index score when compared to the matched controls (0.2 vs 0.008; p Conclusion: For the first time ever, national, longitudinal data regarding age at diagnosis, incidence, hospital contacts, co-morbidity and the mortality rate of HP are presented. We found an increased mortality among HP patients compared with a matched control group without HP. This might indicate, that this rare disease should be centralized to a few centers with high expertise in treatment modalities.
简介:过敏性肺炎(HP)是一种罕见的间质性肺疾病(ILD)，其致死率几乎未被描述。很少有研究在国家层面上调查HP。目的:本研究的目的是调查丹麦全国本病的发病率、生存率和合并症。方法:使用丹麦国家患者登记处，我们确定了1998年至2010年间首次诊断为HP的所有患者。HP患者按性别、年龄、婚姻状况和地理位置与对照组1:4匹配。通过Charlson指数评分探讨诊断前3年的合并症。生存率采用Kaplan-Meier曲线和风险比进行评估。结果:在观察期间，我们确定了753例患者(男性:56.7%)，平均hp发病率为63 /年。超过一半(388例= 51.5%)的患者年龄在50岁以下。与匹配的对照人群相比，HP的存活率在所有时间点都较低。HP患者在最初诊断后的头两年死亡率最高，这表明0-39岁和60-80岁以上年龄组的死亡率更高。此外，与匹配的对照组相比，患者的Charlson指数评分显著更高(0.2 vs 0.008;p结论:有史以来第一次提出了关于HP的诊断年龄、发病率、医院接触、合并症和死亡率的全国纵向数据。我们发现与没有HP的对照组相比，HP患者的死亡率增加。这可能表明，这种罕见的疾病应该集中在少数具有高专业知识的治疗方式的中心。
{"title":"Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: A population-based study","authors":"A. H. Rittig, O. Hilberg, A. Løkke","doi":"10.1183/13993003.CONGRESS-2018.PA3659","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3659","url":null,"abstract":"Introduction: Hypersensitivity pneumonitis (HP) is a rare interstitial lung disease (ILD), with an almost undescribed lethality. Very few studies have investigated HP on a national level. Aim: The aim of this study was to investigate incidence, survival rate and comorbidity of this disease nationwide in Denmark. Methods: Using the Danish National Patient Registry we identified all patients with a first-time diagnosis of HP between 1998 and 2010. Patients with HP were matched 1:4 with controls by gender, age, marital status and geography. Co-morbidity three years prior to diagnosis was explored by the Charlson index score. Survival rates were assessed using Kaplan-Meier curves and Hazard Ratios. Results: We identified 753 patients (men: 56.7%) during the observation period and an average HP-incidence of 63 pr. Year. More than half (388 patients = 51.5%) was below 50 years. Survival rates of HP were lower at all time points when compared to the matched control population. The highest mortality among patients with HP was observed during the first two years following initial diagnosis - revealing a higher mortality rate in the age groups 0-39 and 60-80+. Furthermore, patients had a significant higher Charlson index score when compared to the matched controls (0.2 vs 0.008; p Conclusion: For the first time ever, national, longitudinal data regarding age at diagnosis, incidence, hospital contacts, co-morbidity and the mortality rate of HP are presented. We found an increased mortality among HP patients compared with a matched control group without HP. This might indicate, that this rare disease should be centralized to a few centers with high expertise in treatment modalities.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124145996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA2980
J. Mullerpattan, Pankti Sheth, Aditi V. Joshi, Z. Udwadia
{"title":"Acute exacerbation of ILD: an Indian tertiary centre experience","authors":"J. Mullerpattan, Pankti Sheth, Aditi V. Joshi, Z. Udwadia","doi":"10.1183/13993003.CONGRESS-2018.PA2980","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2980","url":null,"abstract":"","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"2009 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132575278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.OA3816
H. Kim, Minkyu Han, J. Joseph, G. Cross, J. Barnett, D. S. Kim, J. Song
{"title":"A prognostic staging system for rheumatoid arthritis-associated interstitial lung disease","authors":"H. Kim, Minkyu Han, J. Joseph, G. Cross, J. Barnett, D. S. Kim, J. Song","doi":"10.1183/13993003.CONGRESS-2018.OA3816","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA3816","url":null,"abstract":"","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"109 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123112322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.CONGRESS-2018.PA2991
E. Vivarelli, G. Vitiello, Francesco Tinghi, D. Malandrino, B. Palterer, E. Torricelli, E. Bargagli, E. Rosi, P. Parronchi
Introduction: Interstitial lung diseases (ILD) involve lung interstitium and airspaces and can be either idiopathic or a complication of connective tissue diseases (CTD). Interstitial pneumonia with autoimmune features (IPAF) is a recently defined group of ILD showing some CTD features, but without fulfilling classification criteria for CTD. Aim of the study: to describe the main clinical, serological, instrumental and therapeutic features of a cohort of patients referred to our outpatient Immunology Clinic by pulmonologists, after multidisciplinary evaluation. Methods: clinical, laboratory and instrumental data were retrospectively collected from 60 patients. Results: Our cohort was divided into 3 groups: patients with a definite diagnosis of CTD (n=24); IPAF group (n=14); control group (n=22), including patients not fulfilling criteria for IPAF or a CTD, but with isolate presence of ILD. Main data are summarized in the attached figure. Conclusions: Despite the descriptive and retrospective design of our study, these data show that IPAF group exhibits worse lung function and 6MW tests performance, albeit their clinical and serological similarities with CTD. Our CTD group contains a high number of UIP, generally associated to a worse prognosis and linked to the high prevalence of rheumatoid arthritis. Surprisingly, their outcome is better than NSIP-related IPAF group.
{"title":"Autoimmunity in Interstitial lung diseases: preliminary data from a tertiary center.","authors":"E. Vivarelli, G. Vitiello, Francesco Tinghi, D. Malandrino, B. Palterer, E. Torricelli, E. Bargagli, E. Rosi, P. Parronchi","doi":"10.1183/13993003.CONGRESS-2018.PA2991","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA2991","url":null,"abstract":"Introduction: Interstitial lung diseases (ILD) involve lung interstitium and airspaces and can be either idiopathic or a complication of connective tissue diseases (CTD). Interstitial pneumonia with autoimmune features (IPAF) is a recently defined group of ILD showing some CTD features, but without fulfilling classification criteria for CTD. Aim of the study: to describe the main clinical, serological, instrumental and therapeutic features of a cohort of patients referred to our outpatient Immunology Clinic by pulmonologists, after multidisciplinary evaluation. Methods: clinical, laboratory and instrumental data were retrospectively collected from 60 patients. Results: Our cohort was divided into 3 groups: patients with a definite diagnosis of CTD (n=24); IPAF group (n=14); control group (n=22), including patients not fulfilling criteria for IPAF or a CTD, but with isolate presence of ILD. Main data are summarized in the attached figure. Conclusions: Despite the descriptive and retrospective design of our study, these data show that IPAF group exhibits worse lung function and 6MW tests performance, albeit their clinical and serological similarities with CTD. Our CTD group contains a high number of UIP, generally associated to a worse prognosis and linked to the high prevalence of rheumatoid arthritis. Surprisingly, their outcome is better than NSIP-related IPAF group.","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127575672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-15DOI: 10.1183/13993003.congress-2018.pa2983
R. Crișan-Dabija, T. Mihăescu
{"title":"Interstitial lung diseases misdiagnosis: a Healthcare Improvement Science (HIS) approach","authors":"R. Crișan-Dabija, T. Mihăescu","doi":"10.1183/13993003.congress-2018.pa2983","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2983","url":null,"abstract":"","PeriodicalId":178396,"journal":{"name":"ILD/DPLD of known origin","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128395910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：